The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 19, 2024

Filed:

Jun. 08, 2017
Applicant:

Shanghai Jiao Tong University School of Medicine, Shanghai, CN;

Inventors:

Fubin Li, Shanghai, CN;

Xiaobo Liu, Shanghai, CN;

Yan Zhang, Shanghai, CN;

Yingjie Zhao, Shanghai, CN;

Huan Shi, Shanghai, CN;

Huihui Zhang, Shanghai, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); A61P 37/04 (2006.01); C07K 16/00 (2006.01); C07K 16/46 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 39/39 (2013.01); A61K 39/395 (2013.01); A61P 35/00 (2018.01); A61P 37/04 (2018.01); C07K 16/00 (2013.01); C07K 16/28 (2013.01); C07K 16/46 (2013.01); G01N 33/68 (2013.01); C07K 2317/522 (2013.01); C07K 2317/53 (2013.01); C07K 2317/569 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01);
Abstract

Provided herein is a heavy chain constant region comprising a CH1 domain, a hinge region, a CH2 domain and a CH3 domain, wherein the sequences of said CH1 domain and hinge region derive from the sequences of CH1 domain and hinge region in human IgG2, the sequences of said CH2 domain and CH3 domain derive from the sequences of CH2 domain and CH3 domain in human IgGs; and wherein, said antibody heavy chain constant region has an affinity to human FcγRIIB equal to or higher than the affinity of human IgG1 to human FcγRIIB, said antibody heavy chain constant region has an I/A ratio equal to or higher than human IgG1 has. Also provided are antibodies or fusion proteins based on a heavy chain constant region according to the above, wherein the antibody heavy chain constant region significantly enhances agonistic activity of the antibodies or fusion proteins and improves efficacy of the antibodies or fusion proteins in treating diseases like tumors and autoimmune diseases.


Find Patent Forward Citations

Loading…